Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial
Authors
Keywords
-
Journal
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
Volume 43, Issue 6, Pages 616-628
Publisher
Oxford University Press (OUP)
Online
2013-04-30
DOI
10.1093/jjco/hyt054
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Axitinib for the Management of Metastatic Renal Cell Carcinoma
- (2013) Bernard Escudier et al. Drugs in research & development
- Evidence-Based Clinical Practice Guideline for Renal Cell Carcinoma: The Japanese Urological Association 2011 update
- (2012) Tomoaki Fujioka et al. INTERNATIONAL JOURNAL OF UROLOGY
- Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma
- (2011) J. Fruehauf et al. CLINICAL CANCER RESEARCH
- Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma
- (2011) Yoshihiko Tomita et al. EUROPEAN JOURNAL OF CANCER
- Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics
- (2011) Meghan Brennan et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients
- (2011) Yutaka Fujiwara et al. INVESTIGATIONAL NEW DRUGS
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Phase 3 trial of everolimus for metastatic renal cell carcinoma
- (2010) Robert J. Motzer et al. CANCER
- EAU Guidelines on Renal Cell Carcinoma: The 2010 Update
- (2010) Börje Ljungberg et al. EUROPEAN UROLOGY
- Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?
- (2010) Robert Goldstein et al. Expert Review of Anticancer Therapy
- Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients
- (2010) Takeshi Ueda et al. INTERNATIONAL JOURNAL OF UROLOGY
- Kidney Cancer Working Group Report
- (2010) S. Naito et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers
- (2009) Y. K. Pithavala et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: A phase I study in Japanese patients
- (2009) Toru Mukohara et al. CANCER SCIENCE
- Prognosis of Japanese Metastatic Renal Cell Carcinoma Patients in the Cytokine Era: A Cooperative Group Report of 1463 Patients
- (2009) Sei Naito et al. EUROPEAN UROLOGY
- Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma
- (2009) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and Safety of Axitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Phase II Study
- (2009) Joan H. Schiller et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Guideline for Management of the Clinical T1 Renal Mass
- (2009) Steven C. Campbell et al. JOURNAL OF UROLOGY
- Axitinib—a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor
- (2009) Ronan J. Kelly et al. Targeted Oncology
- Emerging ethnic differences in lung cancer therapy
- (2008) I Sekine et al. BRITISH JOURNAL OF CANCER
- Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review
- (2008) Kiran Gupta et al. CANCER TREATMENT REVIEWS
- Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
- (2008) D. D. Hu-Lowe et al. CLINICAL CANCER RESEARCH
- Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study
- (2008) Ezra E.W. Cohen et al. JOURNAL OF CLINICAL ONCOLOGY
- Racial/Ethnic and Gender Disparities in Renal Cell Carcinoma Incidence and Survival
- (2008) Helen Shi Stafford et al. JOURNAL OF UROLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search